Peripheral Neuropathy Secondary to Diabetes
Peripheral neuropathy claimed as secondary to diabetes, most often coded to the sciatic nerve, is the single highest-volume secondary pairing under diabetes anywhere in the Board's published record: 7,653 issues, more than any other diabetic complication veterans file. It's granted 55 percent of the time decided issues reach a merits ruling. The nerve-damage mechanism, why a normal or borderline EMG doesn't end your claim, why there's no rule requiring your diabetes diagnosis to predate your neuropathy, five recent Board decisions dissected, and the evidence that separates the wins.
The Numbers: The Biggest Secondary Pairing Under Diabetes
In the Board's published decisions, peripheral neuropathy (typically coded to DC 8520, paralysis of the sciatic nerve, the most common code used for diabetic lower-extremity neuropathy) claimed as secondary to diabetes (DC 7913) outnumbers every other diabetes-secondary claim in this site's index by a wide margin.
How those 7,653 issues came out
Diabetic peripheral neuropathy can affect several nerves at once (sciatic, femoral, peroneal), often bilaterally, and the Board's published grants below never once turned on the nerve-conduction study alone. Every winning file paired a competent medical opinion with either a specific mechanism, a rebuttal of an alternative cause, or a factual correction the VA's own exam had gotten wrong.
The Mechanism: Chronic Hyperglycemia and Nerve Damage
Diabetic peripheral neuropathy is one of the best-documented complications of diabetes in the medical literature, but the case law shows the actual fight is rarely about whether the general mechanism exists. It's about whether the specific opinion in the veteran's file addresses the veteran's specific facts.
1. Chronic hyperglycemia damages small blood vessels and nerve fibers directly
Sustained high blood sugar injures the vasa nervorum, the small blood vessels that supply peripheral nerves, and directly damages nerve fibers through metabolic pathways. The result is the classic "stocking-glove" pattern of numbness, tingling, and pain, most often starting in the feet.
2. The landmark trial VA's own examiners rarely cite
The Diabetes Control and Complications Trial, a landmark 1993 study, found intensive glycemic control reduced the onset of clinical neuropathy by 60 percent compared to conventional treatment, alongside similar reductions in retinopathy and nephropathy. See DCCT Research Group, The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus, N. Engl. J. Med. 329:977-986 (1993). The flip side of that finding is direct evidence for causation: poor glycemic control measurably raises neuropathy risk.
3. No temporal requirement between the two diagnoses
A recurring argument in VA's denials is that the neuropathy was diagnosed years before diabetes, so it can't be secondary to it. That argument misunderstands the law. Secondary service connection carries no requirement that the primary condition predate the secondary one in diagnosis; a primary disability "need not be service connected, or even diagnosed, at the time the secondary condition is incurred." Frost v. Shulkin, 29 Vet. App. 131 (2017). Pre-diabetes bloodwork, sometimes documented years before a formal Type II diagnosis, has bridged exactly this kind of gap in published grants below.
The Legal Path: 38 CFR § 3.310, and Why "Specifically Relate" Is the Wrong Standard
A secondary service connection claim needs three things (Wallin v. West, 11 Vet. App. 509, 512 (1998)): a current diagnosis, a service-connected primary, and a nexus, by causation or aggravation. Two recurring points separate the wins from the losses in this specific pairing.
"Can't specifically relate it" is not the legal bar
Several VA exams reviewed for this guide declined to connect neuropathy to diabetes because the condition was "multifactorial," citing competing causes like chemotherapy or cardiovascular disease, and stated they "could not specifically relate" the neuropathy to diabetes. The Board has rejected that framing directly: the correct standard is equipoise under 38 U.S.C. § 5107(b), "at least as likely as not," not certainty. An examiner demanding more than that has applied the wrong legal test (Bd. Vet. App. A21009019).
An alternative cause must actually be ruled out, not just floated
Naming a competing explanation, low B12, a cervical spine surgery, alcohol use, "other unspecified causes", is not the same as ruling it out. In one published grant, the Board found a VA opinion blaming B12 deficiency inadequate because it relied on stale, years-old labs rather than current testing, while the winning private opinion affirmatively excluded B12 and alcohol with current labs (Bd. Vet. App. A25038023).
Five Recent Board Decisions Dissected
All five decisions below granted service connection for peripheral neuropathy secondary to diabetes, decided May 2021 through April 2025 before five different Veterans Law Judges. Published Board decisions are not precedent, but the patterns repeat.
"Multifactorial" and a temporal gap, both rejected · Citation A21009019 (May 10, 2021), Hearing docket
The record: bilateral upper- and lower-extremity neuropathy. Three VA exams (2015, 2019, 2020) each gave negative opinions, calling the neuropathy "multifactorial", pointing to a colon-cancer chemotherapy history and cardiovascular disease, and stating the examiner couldn't "specifically relate" it to diabetes. The exams also noted an eight-year gap between neuropathy onset (2004, after colon-cancer surgery) and the diabetes diagnosis (2012).
Why it won: the Board rejected "specifically relate" as the wrong standard, the actual bar is equipoise. It also found the temporal gap irrelevant: "service connection on a secondary basis does not include a temporal requirement... a primary disability need not be service connected, or even diagnosed, at the time the secondary condition is incurred" (citing Frost v. Shulkin).
A straightforward positive-evidence stack, nothing on the other side · Citation 23028950 (May 17, 2023), legacy docket, widow substituted as claimant
The record: a 2009 private endocrinology letter linked the veteran's diabetes to his peripheral neuropathy, VA treatment notes documented "occasional peripheral neuropathy due to DM" since 2001, and a December 2009 VA exam confirmed the diabetic-neuropathy diagnosis. The veteran's widow, substituted as claimant after his 2011 death, testified to his dropped items and inability to wear dress shoes.
Why it won: with a private nexus letter, corroborating VA treatment notes, and a confirming VA exam all pointing the same direction, and no adequate negative opinion anywhere in the file, the claim was granted on the strength of an unopposed record.
A "normal" EMG that ignored a medication masking the symptoms · Citation A24023922 (May 8, 2024), Hearing docket
The record: an August 2018 nerve conduction study came back a "normal test result" with "borderline low amplitude... suggestive of very mild sensory neuropathy," which a VA examiner used as the basis for a negative opinion the following October. The veteran had been taking gabapentin, a neuropathic-pain medication, throughout 2018, testimony at his hearing raised this directly. Multiple VA treatment records independently documented "diabetic neuropathy."
Why it won: the negative opinion never addressed whether the gabapentin was masking the true severity of the veteran's symptoms at the time of testing, a gap that undermined its probative value. Combined with the independent VA treatment-record documentation, the Board found the record supported a grant.
Pre-diabetes bloodwork bridges the timeline gap · Citation A24012423 (Mar. 13, 2024), Hearing docket
The record: a September 2022 VA exam found the neuropathy predated the veteran's formal Type II diabetes diagnosis (December 2021), since he'd been on gabapentin since before 2016. A private physician assistant's opinion countered that the neuropathy's onset actually coincided with the veteran's pre-diabetes diagnosis, not the later formal diabetes diagnosis, supported by the veteran's hearing testimony that he'd had pre-diabetic bloodwork since 2005.
Why it won: the VA exam was discounted for failing to address the pre-diabetes history at all. A formal diagnosis date is not the same as the actual onset of the underlying metabolic disease, and the pre-diabetes evidence bridged what otherwise looked like a fatal timeline problem.
Rationale, not direction, decides which opinion wins · Citation A25038023 (Apr. 24, 2025), Hearing docket, herbicide exposure conceded
The record: three opinions were discounted in this file: an August 2021 VA opinion blamed B12 deficiency using stale 2013 labs with no current testing; a March 2022 private opinion, though positive for the veteran, was conclusory with no supporting rationale and was also given low weight; and a second March 2022 VA opinion cited unspecified "multiple other explanations" without naming or ruling any of them out. The opinion that won was a March 2025 private nurse-practitioner opinion citing a November 2021 nerve conduction study showing small fiber neuropathy, and affirmatively ruling out B12 deficiency and alcohol use with current lab work.
Why it won: probative value turned on rationale and current data, not on which side offered the opinion or which direction it favored. A positive opinion with no reasoning lost just as readily as a negative one built on outdated records.
The pattern across all five
- "Multifactorial" and "can't specifically relate" are not denials on the merits, they're a mismatch between the examiner's stated standard and the actual legal bar of equipoise.
- Timing arguments routinely fail when pre-existing bloodwork, pre-diabetes history, or simply the settled no-temporal-requirement rule fills the gap.
- A "normal" or borderline EMG is not fatal if the opinion relying on it ignores a confound like medication masking symptoms at the time of testing.
- Named-but-unexcluded alternative causes lose, an opinion has to affirmatively rule out a competing explanation with current evidence, not just mention it.
Why VA Denies These Claims, and What the Board Said Back
Each rationale below is drawn from the actual VA examinations in the cases above, alongside how the Board answered it.
| VA examiner's rationale | How the Board answered it |
|---|---|
| Neuropathy is "multifactorial"; examiner "cannot specifically relate" it to diabetes. | Wrong legal standard. The bar is equipoise, "at least as likely as not," not certainty (A21009019). |
| Neuropathy was diagnosed years before the diabetes diagnosis. | No temporal requirement exists for secondary service connection (Frost v. Shulkin); pre-diabetes bloodwork can bridge the gap (A21009019, A24012423). |
| Nerve conduction study came back normal or borderline. | Doesn't defeat the claim if the opinion relying on it ignores a confound, like a neuropathic-pain medication masking symptom severity at testing (A24023922). |
| An alternative cause exists (B12 deficiency, prior surgery, unspecified "other explanations"). | Naming a cause is not ruling it out. An opinion citing an alternative must exclude it with current evidence, not stale records or a bare assertion (A25038023). |
| (From the veteran's side) a positive private opinion with no stated rationale. | Given reduced weight regardless of favoring the veteran; conclusory reasoning loses on either side of the ledger (A25038023). |
Across the Board's full record for peripheral neuropathy, the leading classified denial reason is shown live below.
The Evidence Checklist
What the winning files contained, item by item.
- A documented neuropathy diagnosis: a nerve conduction study or EMG helps, but is not required, several grants above won without one, or despite a normal/borderline result.
- Address medication masking directly: if you're on gabapentin or a similar neuropathic-pain medication, note it and its potential to understate your true symptom severity at the time of any nerve-conduction testing.
- Current lab work, not old records: if your file has a competing explanation on the table (B12 deficiency, alcohol use, an unrelated surgery), current testing that rules it out carries far more weight than a stale reference to old labs.
- Pre-diabetes history if your timeline looks backwards: pre-diabetic bloodwork, sometimes years before a formal Type II diagnosis, can bridge an apparent gap between neuropathy onset and diagnosis date.
- Both causation and aggravation addressed: a nexus opinion silent on aggravation is incomplete under the same doctrine that governs every other secondary claim on this site.
Across all published DC 8520 decisions, files with a private medical opinion track a different grant rate than VA-exam-only files, shown live below.
The Wider Data
Where peripheral neuropathy sits among the conditions veterans claim as secondary to diabetes. Live from the Board's published decisions, refreshed weekly:
Bars are BVA grant rates among decided issues for each condition claimed as secondary to diabetes, with issue counts. Descriptive of the published record, not a prediction about any one claim. Explore the underlying decisions in BVA Decision Search.
If Granted: The Rating
Peripheral nerve conditions are rated under 38 CFR § 4.124a by the specific nerve involved and the severity of impairment, mild, moderate, moderately severe, or severe incomplete paralysis, up to complete paralysis. DC 8520 (sciatic nerve) is the most common code for diabetic lower-extremity neuropathy, but femoral (DC 8526), peroneal (DC 8521), and upper-extremity nerves can also be involved, sometimes several at once. When both legs are affected, the bilateral factor applies. Each affected nerve is typically rated separately, then combined under VA math rather than added, run it in the VA Math Calculator. Full complication detail for diabetes is in the general Diabetes Claims Guide.
Frequently Asked Questions
Why is this the single biggest secondary claim under diabetes?
Volume, 7,653 published issues, more than any other diabetes-secondary pairing in this site's index, reflecting how common diabetic peripheral neuropathy is as a real medical complication. The 55 percent grant rate is solid but not automatic; the losses in this pool consistently trace back to a VA opinion that either applied the wrong legal standard or left a real gap in its reasoning that the veteran's side didn't close.
My EMG or nerve conduction study came back normal. Does that end my claim?
Not necessarily. In one published grant, a "normal" test with a borderline finding was the basis for a negative VA opinion that never addressed the veteran's gabapentin use, a medication that can mask true symptom severity at the time of testing. The Board discounted the opinion on that gap (A24023922).
My neuropathy was diagnosed before my diabetes. Can I still win?
Yes. Secondary service connection carries no requirement that the primary condition predate the secondary one in diagnosis (Frost v. Shulkin, 29 Vet. App. 131 (2017)). Pre-diabetes bloodwork, documented years before a formal diagnosis, has bridged this exact gap in published grants.
My VA exam says my neuropathy is "multifactorial" and can't be specifically related to diabetes. Is that a real denial?
Read it carefully. The Board has rejected "cannot specifically relate" as the wrong legal standard; the actual bar is equipoise, "at least as likely as not," not certainty (A21009019).
Does it matter which nerve is affected?
The DC code changes (sciatic 8520, femoral 8526, peroneal 8521, and others), and diabetic neuropathy commonly affects more than one nerve, often bilaterally. The underlying secondary-connection legal theory is the same regardless of which nerve is coded.
Do I need a private doctor to win, or can VA's own records carry the claim?
Either can work. One grant above ran entirely on a private endocrinology letter and corroborating VA treatment notes with no competing negative opinion in the file. What consistently mattered across all five cases was whether the reasoning, whichever side it came from, actually engaged the veteran's specific facts.
Sources
- Bd. Vet. App. A21009019 (May 10, 2021); 23028950 (May 17, 2023); A24023922 (May 8, 2024); A24012423 (Mar. 13, 2024); A25038023 (Apr. 24, 2025) (published, non-precedential).
- 38 U.S.C. §§ 1110, 1131, 5107; 38 CFR §§ 3.102, 3.303, 3.310, 4.124a (peripheral nerve codes including DC 8520), 4.119 (DC 7913).
- Wallin v. West, 11 Vet. App. 509 (1998); Allen v. Brown, 7 Vet. App. 439 (1995) (en banc); Frost v. Shulkin, 29 Vet. App. 131 (2017); Shedden v. Principi, 381 F.3d 1163 (Fed. Cir. 2004); Holton v. Shinseki, 557 F.3d 1362 (Fed. Cir. 2009); Ward v. Wilkie, 31 Vet. App. 233 (2019); Barr v. Nicholson, 21 Vet. App. 303 (2007); Gilbert v. Derwinski, 1 Vet. App. 49 (1990).
- Diabetes Control and Complications Trial (DCCT) Research Group, The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus, N. Engl. J. Med. 329:977-986 (1993), PMID 8366922.
- Aggregate outcome counts: RateMyVSO index of published BVA decisions (as of July 2026 for the static chart; live widgets refresh weekly).